key: cord-0905643-w369wq2p authors: Krisai, Philipp; Roten, Laurent; Zeljkovic, Ivan; Pavlovic, Nikola; Ammann, Peter; Reichlin, Tobias; Auf der Maur, Eric; Streicher, Olivia; Knecht, Sven; Kühne, Michael; Osswald, Stefan; Novak, Jan; Sticherling, Christian title: Prospective Evaluation of a Standardized Screening for Atrial Fibrillation after Ablation of Cavotricuspid Isthmus Dependent Atrial Flutter date: 2021-09-28 journal: J Clin Med DOI: 10.3390/jcm10194453 sha: 7275cd9a985b214ba860c60ff5dbb893faaa3e3f doc_id: 905643 cord_uid: w369wq2p Aims: We aimed to prospectively investigate the effectiveness of a standardized follow-up for AF-detection after common atrial flutter (cAFL) ablation. Methods: A total of 309 patients after cAFL ablation without known AF, from 5 centers, and at least one completed, standardized follow-up at 3, 6 and 12 months, including a 24 h Holter-electrocardiogram (ECG), were included. The primary outcome was incident atrial fibrillation (AF), or atrial tachycardia (AT). Predictors were investigated by Cox proportional-hazards models. Results: The mean age was 67.9 years; 15.2% were female and the mean CHA(2)DS(2)-VASc (Congestive heart failure, Hypertension, Age, Diabetes, Stroke, Vascular disease, Sex category) score was 2.4 points. The great majority of patients (90.3%) were anticoagulated. Over a mean follow-up of 12.2 months with a standardized approach, AF/AT was detected in 73 patients, corresponding to 11.7% at 3 months, 18.4% at 6 months and 28.2% at 12 months of follow-up. AF was found in 64 patients, AT in 9 and both in 2 patients. Occurrence of AF was recorded in 40 (60.6%) patients by Holter-ECG and in the remaining 26 (39.4%) by clinical follow-up only. There was no difference in male versus female (p = 0.08), or in younger versus older patients (p = 0.96) for AF/AT detection. Only coronary artery disease (hazard ratio [95% confidence intervals] 1.03 [1.01–1.05], p = 0.01) was associated with the primary outcome. Conclusions: AF or AT was detected in a large proportion of cAFL patients after cavotricuspid-isthmus (CTI) ablation, using a standardized follow-up over 1 year. This standardized screening can be easily implemented with high patient acceptance. The high proportion of post-ablation AF needs to be taken into consideration when deciding on long-term oral anticoagulation. Atrial fibrillation (AF) and cavotricuspid-isthmus (CTI) dependent, common atrial flutter (cAFL) frequently coexist [1, 2] . Both arrhythmias share not only risk factors, but also direct arrhythmia mechanisms [3] . In the majority of cAFL patients, AF or supraventricular ectopy seems to be necessary to cause functional blockage between the vena cava, in order to enable re-entrant cAFL [4, 5] . This close relationship between cAFL and AF has important clinical implications for patients presenting with lone cAFL, most importantly regarding the decision on long-term anticoagulation therapy. Currently, clear guideline recommendations are lacking for the preferred AF screening intensity or duration in cAFL patients after CTI catheter ablation [6] . Thus, clinicians are left in uncertainty about how to follow up with these patients in an efficient way. We previously reported an AF incidence rate of 30%, with a follow-up of approximately two years in cAFL patients after CTI ablation in a retrospective analysis, with less stringent rhythm monitoring in one of the largest populations so far [2] . Based on these results, we set up a prospective, multi-center cohort study, to investigate the effectiveness and clinical utility of a standardized follow-up for AF screening after cAFL ablation. We also aimed to study independent predictors for AF occurrence, in order to be able to allocate screening resources to those patients who might benefit the most. Patients of the ongoing, prospective, multicenter BEAT-Flutter registry, with at least one follow-up visit, were included. In this registry, all patients undergoing CTI dependent cAFL ablation at five centers (four in Switzerland, one in Croatia) were included, from January 2017 to March 2021. Exclusion criteria were: patient refusal to participate, non-CTI-dependent AFL, prior heart surgery, and congenital heart disease. For the current exploratory analyses within the registry, we extracted the data in July 2021, and excluded all patients with a history of AF. The study flow is shown in Figure 1 . Data acquisition and analysis were performed in compliance with protocols approved by the Ethical Committee Nordwest-und-Zentralschweiz (ethical approval number 2016-01865). Written informed consent was obtained from all participants prior to the study. The study was carried out according to the principles of the Declaration of Helsinki. The data supporting this study are available from the corresponding author upon reasonable request. Trained study personnel, using standardized questionnaires, obtained information on patient characteristics including demographics, medical history, and risk factors, during a clinical study visit on enrolment. We used the European Heart Rhythm Association (EHRA) score for symptom assessment. The EHRA score ranges from I to IV, with I indicating no symptoms, II indicating mild symptoms, III indicating severe symptoms, and IV indicating disabling symptoms [6] . We also assessed individual symptoms, including palpitations, angina pectoris, dizziness or syncope, and dyspnea. After catheter ablation for cAFL, patients were followed-up at three, six and twelve months at clinical outpatient visits, including 12-lead ECGs and 24 h Holter-ECGs at each visit. AF or AT had to be present for at least 30 s to be considered relevant. Follow-up visits were recommended to take place ±1 month for the 3-and 6-month follow-up visits and ±3 months for the 12-month follow-up visit. Patients were additionally advised to obtain ECG documentation, in case of arrhythmia symptoms at unscheduled clinical follow-ups. A linear lesion from the tricuspid annulus to the inferior vena cava was performed by radiofrequency ablation at 30-40 Watts, with either a non-irrigated 8 mm, or irrigated 3.5 mm tip catheter, under fluoroscopic and electrocardiogram guidance. The procedural endpoint was a bi-directional conduction block across the CTI [7] . Oral anticoagulation was not interrupted for the procedure. Trained study personnel, using standardized questionnaires, obtained information on patient characteristics including demographics, medical history, and risk factors, dur ing a clinical study visit on enrolment. We used the European Heart Rhythm Association (EHRA) score for symptom assessment. The EHRA score ranges from I to IV, with I indi cating no symptoms, II indicating mild symptoms, III indicating severe symptoms, and IV indicating disabling symptoms [6] . We also assessed individual symptoms, including palpitations, angina pectoris, dizziness or syncope, and dyspnea. After catheter ablation for cAFL, patients were followed-up at three, six and twelve months at clinical outpatien visits, including 12-lead ECGs and 24 h Holter-ECGs at each visit. AF or AT had to be present for at least 30 s to be considered relevant. Follow-up visits were recommended to take place ±1 month for the 3-and 6-month follow-up visits and ±3 months for the 12 month follow-up visit. Patients were additionally advised to obtain ECG documentation in case of arrhythmia symptoms at unscheduled clinical follow-ups. A linear lesion from the tricuspid annulus to the inferior vena cava was performed by radiofrequency ablation at 30-40 Watts, with either a non-irrigated 8 mm, or irrigated 3.5 mm tip catheter, under fluoroscopic and electrocardiogram guidance. The procedura The primary outcome was incident AF, or atrial tachycardia (AT), detected in a 12-lead ECG or 24 h Holter-ECG after catheter ablation of cAFL. AF or AT had to be confirmed by a cardiologist and present for at least 30 s. Secondary outcomes were the individual components of the primary outcome, and recurrence of cAFL. Adverse outcomes included hospitalization for congestive heart failure (CHF), stroke or transient ischemic attack (TIA), major or clinically relevant non-major bleeding, cardiovascular death, and overall mortality. Hospitalization for CHF was defined as at least one overnight stay in the hospital with symptoms and signs of CHF. Stroke was defined as a new focal neurological dysfunction with clinical, imaging, or pathological evidence of focal infarction due to ischemic, hemorrhagic or undetermined origin. Major bleeding included fatal bleeding, symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial or intramuscular with compartment syndrome), and bleeding causing a fall in hemoglobin level of ≥2 g/dL within 7 days, or leading to a transfusion of ≥2 units of blood transfusion. Cardiovascular death included any death with documented cardiovascular origin, and included fatal bleedings. Standardized validation of study outcomes was performed by independent physicians. Baseline characteristics were shown as unstratified. The distribution of continuous variables was checked by visual inspection of the histogram, and evaluation of skewness and kurtosis. As all variables were normally distributed, they were presented as means (±standard deviations (SD)). Categorical variables were presented as counts (percentages). Kaplan-Meier survival curves were built to assess the incidence of AF or AT after cAFL ablation. Sensitivity analyses included stratification for sex and age (